New: Biosimilars strategies introduced.
Close
Valuable and timely information on drug therapy issues impacting today's health care and pharmacy environment.
May 21, 2018 - The FDA announced the approval of Dova Pharmaceuticals’ Doptelet (avatrombopag) for the treatment of thrombocytopenia in adult patients with chronic liver disease (CLD) who are scheduled to undergo a procedure.
Download PDF
Return to publications
